Redx pharma (REDX.LON) owns RXC005 global IP rights, with key composition-of-matter patents expected to extend up until 2035Full report is available via Capital Network website
Avacta (AVCT.LON), a UK-based biotechnology company, has developed an innovative proteinscaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.
On April 3rd Avacta (AVCT.LON) released the results of a pre-clinical study showing that Affimers have an immunogenicity profile comparable to widely used biotech drugs. This leaves Avacta (AVCT.LON) on track to move their immuno-oncology therapeutic Affimer into the clinic by 2019.
Concepta is a small UK-based company that focuses on the development and commercialization of its medical diagnostic device MyLotus. The device, a consumer good, has been developed to improve the probability of conception for women with unexplained infertility (not pregnant after 12+ months trying).